Christopher Hall
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Christopher Hall has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Christian Cole
University of Dundee
5 shared publications - Emily Jefferson
Health Informatics Centre, University of Dundee, Dundee, United Kingdom
4 shared publications - Shahzad Mumtaz
School of Natural and Computing Sciences, University of Aberdeen, Aberdeen AB24 3UE, UK
4 shared publications - Chuang Gao
Health Informatics Centre, School of Medicine, University of Dundee, Dundee, United Kingdom
3 shared publications - Magalie Guignard-Duff
Health Informatics Centre, School of Medicine, University of Dundee, Dundee, United Kingdom
3 shared publications - Bruce Guthrie
Advanced Care Research Centre, Usher Institute, University of Edinburgh, Edinburgh, UK
2 shared publications
Latest Publications
- Open Access
- 16 January 2025
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 27, e52385
A Digital Tool for Clinical Evidence–Driven Guideline Development by Studying Properties of Trial Eligible and Ineligible Populations: Development and Usability Study
Background: Clinical guideline development preferentially relies on evidence from randomized controlled trials (RCTs). RCTs are gold-standard methods to evaluate the efficacy of treatments with the highest internal validity but limited external validity, in the sense that their findings may not always be applicable to or generalizable to clinical populations or population characteristics. The external validity of RCTs for the clinical population is constrained by the lack of tailored epidemiological data analysis designed for this purpose due to data governance, consistency of disease or condition definitions, and reduplicated effort in analysis code. Objective: This study aims to develop a digital tool that characterizes the overall population and differences between clinical trial eligible and ineligible populations from the clinical populations of a disease or condition regarding demography (eg, age, gender, ethnicity), comorbidity, coprescription, hospitalization, and mortality. Currently, the process is complex, onerous, and time-consuming, whereas a real-time tool may be used to rapidly inform a guideline developer’s judgment about the applicability of evidence. Methods: The National Institute for Health and Care Excellence—particularly the gout guideline development group—and the Scottish Intercollegiate Guidelines Network guideline developers were consulted to gather their requirements and evidential data needs when developing guidelines. An R Shiny (R Foundation for Statistical Computing) tool was designed and developed using electronic primary health care data linked with hospitalization and mortality data built upon an optimized data architecture. Disclosure control mechanisms were built into the tool to ensure data confidentiality. The tool was deployed within a Trusted Research Environment, allowing only trusted preapproved researchers to conduct analysis. Results: The tool supports 128 chronic health conditions as index conditions and 161 conditions as comorbidities (33 in addition to the 128 index conditions). It enables 2 types of analyses via the graphic interface: overall population and stratified by user-defined eligibility criteria. The analyses produce an overview of statistical tables (eg, age, gender) of the index condition population and, within the overview groupings, produce details on, for example, electronic frailty index, comorbidities, and coprescriptions. The disclosure control mechanism is integral to the tool, limiting tabular counts to meet local governance needs. An exemplary result for gout as an index condition is presented to demonstrate the tool’s functionality. Guideline developers from the National Institute for Health and Care Excellence and the Scottish Intercollegiate Guidelines Network provided positive feedback on the tool. Conclusions: The tool is a proof-of-concept, and the user feedback has demonstrated that this is a step toward computer-interpretable guideline development. Using the digital tool can potentially improve evidence-driven guideline development through the availability of real-world data in real time.
- 16 January 2025
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 27, e52385
Open AccessA Digital Tool for Clinical Evidence–Driven Guideline Development by Studying Properties of Trial Eligible and Ineligible Populations: Development and Usability Study
Background: Clinical guideline development preferentially relies on evidence from randomized controlled trials (RCTs). RCTs are gold-standard methods to evaluate the efficacy of treatments with the highest internal validity but limited external validity, in the sense that their findings may not always be applicable to or generalizable to clinical populations or population characteristics. The external validity of RCTs for the clinical population is constrained by the lack of tailored epidemiological data analysis designed for this purpose due to data governance, consistency of disease or condition definitions, and reduplicated effort in analysis code. Objective: This study aims to develop a digital tool that characterizes the overall population and differences between clinical trial eligible and ineligible populations from the clinical populations of a disease or condition regarding demography (eg, age, gender, ethnicity), comorbidity, coprescription, hospitalization, and mortality. Currently, the process is complex, onerous, and time-consuming, whereas a real-time tool may be used to rapidly inform a guideline developer’s judgment about the applicability of evidence. Methods: The National Institute for Health and Care Excellence—particularly the gout guideline development group—and the Scottish Intercollegiate Guidelines Network guideline developers were consulted to gather their requirements and evidential data needs when developing guidelines. An R Shiny (R Foundation for Statistical Computing) tool was designed and developed using electronic primary health care data linked with hospitalization and mortality data built upon an optimized data architecture. Disclosure control mechanisms were built into the tool to ensure data confidentiality. The tool was deployed within a Trusted Research Environment, allowing only trusted preapproved researchers to conduct analysis. Results: The tool supports 128 chronic health conditions as index conditions and 161 conditions as comorbidities (33 in addition to the 128 index conditions). It enables 2 types of analyses via the graphic interface: overall population and stratified by user-defined eligibility criteria. The analyses produce an overview of statistical tables (eg, age, gender) of the index condition population and, within the overview groupings, produce details on, for example, electronic frailty index, comorbidities, and coprescriptions. The disclosure control mechanism is integral to the tool, limiting tabular counts to meet local governance needs. An exemplary result for gout as an index condition is presented to demonstrate the tool’s functionality. Guideline developers from the National Institute for Health and Care Excellence and the Scottish Intercollegiate Guidelines Network provided positive feedback on the tool. Conclusions: The tool is a proof-of-concept, and the user feedback has demonstrated that this is a step toward computer-interpretable guideline development. Using the digital tool can potentially improve evidence-driven guideline development through the availability of real-world data in real time.
- 2 January 2025
- Published by Elsevier in Journal of Biomedical Informatics
- Vol. 162, 104771
A pipeline for harmonising NHS Scotland laboratory data to enable national-level analyses
- 2 January 2025
- Published by Elsevier in Journal of Biomedical Informatics
- Vol. 162, 104771
A pipeline for harmonising NHS Scotland laboratory data to enable national-level analyses
- Open Access
- 11 October 2023
- Published by Swansea University in International Journal of Population Data Science
- Vol. 8 (6)
The Health Informatics Centre: a Regional Safe Haven and Trusted Research Environment Enabling World-Leading Research
IntroductionThe Health Informatics Centre (HIC) is a regional Scottish Safe Haven dedicated to secure data management, ensuring its integrity, confidentiality, and availability through a robust information governance framework. MethodsAs a data processor, HIC is responsible for the secure curation, storage, and provision of research data extracts. Research-ready data are made available to approved researchers via our customisable cloud Trusted Research Environment (TRE). ResultsThe available granular data spans over 20 years, includes 2.1 million of the Scottish population, and HIC offers more than 170 datasets, with the most commonly used published with a digital object identifier. Data sources include clinical, hospital, laboratory, imaging, and research datasets which can be linked to new, and existing datasets. The data is quality-assured and released as project-specific extracts, ensuring robust privacy protection and research readiness. HIC's infrastructure is secure-by-design and supports high-performance computing, advanced data analytics, and is customisable to researcher's needs. ConclusionHIC has a long history of supporting a wide range of data-led research projects as a trusted and capable partner. At the time of publication 175 projects across academia, the NHS, and public sector organisations are active within HIC. Through adaptability, innovation and investment in people and infrastructure we have established a sustainable model which will continue to meet future needs and demands from world-leading research with sensitive data.
- 11 October 2023
- Published by Swansea University in International Journal of Population Data Science
- Vol. 8 (6)
Open AccessThe Health Informatics Centre: a Regional Safe Haven and Trusted Research Environment Enabling World-Leading Research
IntroductionThe Health Informatics Centre (HIC) is a regional Scottish Safe Haven dedicated to secure data management, ensuring its integrity, confidentiality, and availability through a robust information governance framework. MethodsAs a data processor, HIC is responsible for the secure curation, storage, and provision of research data extracts. Research-ready data are made available to approved researchers via our customisable cloud Trusted Research Environment (TRE). ResultsThe available granular data spans over 20 years, includes 2.1 million of the Scottish population, and HIC offers more than 170 datasets, with the most commonly used published with a digital object identifier. Data sources include clinical, hospital, laboratory, imaging, and research datasets which can be linked to new, and existing datasets. The data is quality-assured and released as project-specific extracts, ensuring robust privacy protection and research readiness. HIC's infrastructure is secure-by-design and supports high-performance computing, advanced data analytics, and is customisable to researcher's needs. ConclusionHIC has a long history of supporting a wide range of data-led research projects as a trusted and capable partner. At the time of publication 175 projects across academia, the NHS, and public sector organisations are active within HIC. Through adaptability, innovation and investment in people and infrastructure we have established a sustainable model which will continue to meet future needs and demands from world-leading research with sensitive data.
- Open Access
- 1 September 2023
- Published by JMIR Publications Inc. in JMIR Preprints
A Digital Tool for Clinical Evidence–Driven Guideline Development by Studying Properties of Trial Eligible and Ineligible Populations: Development and Usability Study (Preprint)
BACKGROUND Clinical guideline development preferentially relies on evidence from randomized controlled trials (RCTs). RCTs are gold-standard methods to evaluate the efficacy of treatments with the highest internal validity but limited external validity, in the sense that their findings may not always be applicable to or generalizable to clinical populations or population characteristics. The external validity of RCTs for the clinical population is constrained by the lack of tailored epidemiological data analysis designed for this purpose due to data governance, consistency of disease or condition definitions, and reduplicated effort in analysis code. OBJECTIVE This study aims to develop a digital tool that characterizes the overall population and differences between clinical trial eligible and ineligible populations from the clinical populations of a disease or condition regarding demography (eg, age, gender, ethnicity), comorbidity, coprescription, hospitalization, and mortality. Currently, the process is complex, onerous, and time-consuming, whereas a real-time tool may be used to rapidly inform a guideline developer’s judgment about the applicability of evidence. METHODS The National Institute for Health and Care Excellence—particularly the gout guideline development group—and the Scottish Intercollegiate Guidelines Network guideline developers were consulted to gather their requirements and evidential data needs when developing guidelines. An R Shiny (R Foundation for Statistical Computing) tool was designed and developed using electronic primary health care data linked with hospitalization and mortality data built upon an optimized data architecture. Disclosure control mechanisms were built into the tool to ensure data confidentiality. The tool was deployed within a Trusted Research Environment, allowing only trusted preapproved researchers to conduct analysis. RESULTS The tool supports 128 chronic health conditions as index conditions and 161 conditions as comorbidities (33 in addition to the 128 index conditions). It enables 2 types of analyses via the graphic interface: overall population and stratified by user-defined eligibility criteria. The analyses produce an overview of statistical tables (eg, age, gender) of the index condition population and, within the overview groupings, produce details on, for example, electronic frailty index, comorbidities, and coprescriptions. The disclosure control mechanism is integral to the tool, limiting tabular counts to meet local governance needs. An exemplary result for gout as an index condition is presented to demonstrate the tool’s functionality. Guideline developers from the National Institute for Health and Care Excellence and the Scottish Intercollegiate Guidelines Network provided positive feedback on the tool. CONCLUSIONS The tool is a proof-of-concept, and the user feedback has demonstrated that this is a step toward computer-interpretable guideline development. Using the digital tool can potentially improve evidence-driven guideline development through the availability of real-world data in real time.
- 1 September 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessA Digital Tool for Clinical Evidence–Driven Guideline Development by Studying Properties of Trial Eligible and Ineligible Populations: Development and Usability Study (Preprint)
BACKGROUND Clinical guideline development preferentially relies on evidence from randomized controlled trials (RCTs). RCTs are gold-standard methods to evaluate the efficacy of treatments with the highest internal validity but limited external validity, in the sense that their findings may not always be applicable to or generalizable to clinical populations or population characteristics. The external validity of RCTs for the clinical population is constrained by the lack of tailored epidemiological data analysis designed for this purpose due to data governance, consistency of disease or condition definitions, and reduplicated effort in analysis code. OBJECTIVE This study aims to develop a digital tool that characterizes the overall population and differences between clinical trial eligible and ineligible populations from the clinical populations of a disease or condition regarding demography (eg, age, gender, ethnicity), comorbidity, coprescription, hospitalization, and mortality. Currently, the process is complex, onerous, and time-consuming, whereas a real-time tool may be used to rapidly inform a guideline developer’s judgment about the applicability of evidence. METHODS The National Institute for Health and Care Excellence—particularly the gout guideline development group—and the Scottish Intercollegiate Guidelines Network guideline developers were consulted to gather their requirements and evidential data needs when developing guidelines. An R Shiny (R Foundation for Statistical Computing) tool was designed and developed using electronic primary health care data linked with hospitalization and mortality data built upon an optimized data architecture. Disclosure control mechanisms were built into the tool to ensure data confidentiality. The tool was deployed within a Trusted Research Environment, allowing only trusted preapproved researchers to conduct analysis. RESULTS The tool supports 128 chronic health conditions as index conditions and 161 conditions as comorbidities (33 in addition to the 128 index conditions). It enables 2 types of analyses via the graphic interface: overall population and stratified by user-defined eligibility criteria. The analyses produce an overview of statistical tables (eg, age, gender) of the index condition population and, within the overview groupings, produce details on, for example, electronic frailty index, comorbidities, and coprescriptions. The disclosure control mechanism is integral to the tool, limiting tabular counts to meet local governance needs. An exemplary result for gout as an index condition is presented to demonstrate the tool’s functionality. Guideline developers from the National Institute for Health and Care Excellence and the Scottish Intercollegiate Guidelines Network provided positive feedback on the tool. CONCLUSIONS The tool is a proof-of-concept, and the user feedback has demonstrated that this is a step toward computer-interpretable guideline development. Using the digital tool can potentially improve evidence-driven guideline development through the availability of real-world data in real time.
- Open Access
- 9 March 2022
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 24 (3) , e31684
A National Network of Safe Havens: Scottish Perspective
For over a decade, Scotland has implemented and operationalized a system of Safe Havens, which provides secure analytics platforms for researchers to access linked, deidentified electronic health records (EHRs) while managing the risk of unauthorized reidentification. In this paper, a perspective is provided on the state-of-the-art Scottish Safe Haven network, including its evolution, to define the key activities required to scale the Scottish Safe Haven network’s capability to facilitate research and health care improvement initiatives. A set of processes related to EHR data and their delivery in Scotland have been discussed. An interview with each Safe Haven was conducted to understand their services in detail, as well as their commonalities. The results show how Safe Havens in Scotland have protected privacy while facilitating the reuse of the EHR data. This study provides a common definition of a Safe Haven and promotes a consistent understanding among the Scottish Safe Haven network and the clinical and academic research community. We conclude by identifying areas where efficiencies across the network can be made to meet the needs of population-level studies at scale.
- 9 March 2022
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 24 (3) , e31684
Open AccessA National Network of Safe Havens: Scottish Perspective
For over a decade, Scotland has implemented and operationalized a system of Safe Havens, which provides secure analytics platforms for researchers to access linked, deidentified electronic health records (EHRs) while managing the risk of unauthorized reidentification. In this paper, a perspective is provided on the state-of-the-art Scottish Safe Haven network, including its evolution, to define the key activities required to scale the Scottish Safe Haven network’s capability to facilitate research and health care improvement initiatives. A set of processes related to EHR data and their delivery in Scotland have been discussed. An interview with each Safe Haven was conducted to understand their services in detail, as well as their commonalities. The results show how Safe Havens in Scotland have protected privacy while facilitating the reuse of the EHR data. This study provides a common definition of a Safe Haven and promotes a consistent understanding among the Scottish Safe Haven network and the clinical and academic research community. We conclude by identifying areas where efficiencies across the network can be made to meet the needs of population-level studies at scale.